2025-11-15 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly (LLY) based on the provided data, presented in a structured report format with an emphasis on clarity and actionable insights.

**Report: Eli Lilly & Co. (LLY) Stock Analysis**

**1. Performance Overview**

*   **Ticker:** LLY
*   **Company Description:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

*   **Key Performance Metrics:**
    *   **Cumulative Return (LLY):** 291.22%
    *   **Cumulative Return (S&P 500/VOO):** 98.45%
    *   **Absolute Divergence (LLY vs. VOO):** 162.6
    *   **Relative Divergence:** 69.5 (Indicates LLY's performance is in the upper range of its historical divergence from the S&P 500)

*   **Analysis:** LLY has significantly outperformed the S&P 500. The relative divergence suggests this outperformance is substantial compared to its historical trends.

*   **Alpha/Beta Analysis Table:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2015-2017  | 11.0% | 76.1% | -17.0% | -0.0 | 75.6   |
| 2016-2018  | 39.0% | 68.9% | 24.0% | 0.1  | 103.6  |
| 2017-2019  | 41.0% | 68.9% | 19.0% | 0.4  | 117.6  |
| 2018-2020  | 34.0% | 79.8% | 10.0% | 0.3  | 151.1  |
| 2019-2021  | 53.0% | 79.8% | 7.0%  | 0.5  | 247.2  |
| 2020-2022  | 64.0% | 79.8% | 65.0% | 0.4  | 327.4  |
| 2021-2023  | 125.0% | 78.9% | 124.0%| 0.2  | 521.7  |
| 2022-2024  | 134.0% | 81.2% | 113.0%| 0.2  | 691.0  |
| 2023-2025  | 183.0% | 83.5% | 120.0%| 0.2  | 917.6  |

*   **Table Analysis:**
    *   **CAGR:**  Increasing CAGR over recent periods indicates accelerating growth.
    *   **MDD:** Relatively high Maximum Drawdown (MDD) suggests potential volatility.
    *   **Alpha:**  Consistently positive and, in recent years, very high alpha indicates strong outperformance relative to the market.
    *   **Beta:** Low Beta values (close to 0) suggest the stock is less sensitive to overall market movements than the S&P500.
    *   **Market Cap:** Exponential growth in market capitalization reflecting strong investor confidence.

**2. Recent Price Action**

*   **Current Price:** 1025.28
*   **Previous Close:** 1021.37
*   **Change:** 0.38%
*   **Moving Averages:**
    *   **5-day MA:** 1004.24
    *   **20-day MA:** 894.57
    *   **60-day MA:** 810.96

*   **Analysis:** The price is above all three moving averages, indicating a strong uptrend. The 5-day MA being above the 20-day MA, which is above the 60-day MA, further confirms this. The slight positive change from the previous close indicates continued momentum, though not as dramatic as previous days.

**3. Technical Indicators & Forward-Looking Metrics**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 83.51 (Overbought)
*   **PPO:** 1.38 (Positive Momentum)
*   **Hybrid Signal:** Buy 100% of cash (1 shares - Very Safe - MRI:0.90).  Monthly invest 0.8% of total investment ($1,000.00).  Cash Ratio: 0% on 2025-11-03.
*   **Delta_Previous_Relative_Divergence:** 18.0 (+) (Short-term Increase)
*   **Expected Return:** 71.8% (Long-term, relative to S&P 500)

*   **Analysis:**
    *   The MRI suggests a medium level of risk, supporting investment.
    *   The RSI indicates that the stock is currently overbought, which could signal a potential pullback or consolidation in the short term.
    *   The positive PPO confirms positive momentum.
    *   The hybrid signal recommends investment, aligning with the MRI.
    *   A recent increase in relative divergence further highlights recent outperformance.
    *   The high expected return indicates significant potential for long-term outperformance.
    *   The positive price change (0.38%) signals continued positive momentum.

**4. Recent News & Analyst Opinions**

*   **Key Headlines:**
    *   Eli Lilly (LLY): Evaluating Valuation as Growth Momentum Builds (Simply Wall St.)
    *   Stocks to Watch Recap: Alphabet, Walmart, Eli Lilly, Warner Bros. (The Wall Street Journal)
    *   Eli Lilly Leads Three Stocks Near Buy Points (Investor's Business Daily)
*   **Analysis:** Recent news suggests a focus on valuation amid strong growth and identifies LLY as a leader among stocks to watch.

*   **Analyst Consensus:**
    *   **Consensus:** Buy
    *   **Mean Rating:** 1.77 (~Buy)
    *   **Target Price:** 1003.15 (Average) / 1500.00 (High) / 770.00 (Low)
*   **Analysis:**  Analysts generally have a positive outlook on LLY. The current price is trading above the average price target but well below the high price target. This suggests potential upside if the stock reaches the higher end of analyst expectations.

**5. Recent Earnings Analysis**

| 날짜         | EPS  | 매출      |
|--------------|------|-----------|
| 2025-10-30   | 6.22 | 17.60 B$  |
| 2025-08-07   | 6.3  | 15.56 B$  |
| 2025-05-01   | 3.07 | 12.73 B$  |
| 2024-10-30   | 1.08 | 11.44 B$  |
| 2025-10-30   | 1.08 | 11.44 B$  |

*   **Analysis:** EPS and Revenue have shown strong growth.  There appears to be a duplicate entry for 2025-10-30 with significantly different values, which needs clarification. Assuming the higher EPS and Revenue are correct, the company shows solid financial performance.

**6. Financial Information**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $23.79B   | 23.46%  |
| 2025-06-30   | $18.27B   | 30.98%  |
| 2025-03-31   | $15.76B   | 17.50%  |
| 2024-12-31   | $14.19B   | 31.07%  |
| 2024-09-30   | $14.24B   | 6.81%   |

*   **Analysis:**
    *   **Revenue & Profit Margin:**  Revenue is increasing steadily, accompanied by consistently high profit margins (above 80%), indicating strong pricing power and efficient operations.
    *   **Equity & ROE:** Equity is growing, and the Return on Equity (ROE) is generally high, demonstrating the company's effectiveness in generating profits from shareholders' investments. However, there are some fluctuations in ROE, warranting further investigation to understand the underlying causes.

**7. 종합/Overall Summary and Recommendation**

Eli Lilly (LLY) presents a compelling investment case based on strong historical outperformance, accelerating growth, and positive analyst sentiment.

*   **Strengths:**
    *   Significant outperformance vs. S&P 500.
    *   Strong and accelerating revenue and earnings growth.
    *   Very high profit margins and ROE.
    *   Positive analyst ratings and news sentiment.
    *   Low Beta (market risk) and high Alpha.

*   **Weaknesses:**
    *   High MDD (potential volatility).
    *   Overbought RSI, suggesting a possible short-term pullback.
    *   The price is already above the average analyst target price.

*   **Recommendation:**

    *   LLY is a **Buy** for long-term investors, particularly those seeking growth and outperformance. Consider a **dollar-cost averaging** strategy to mitigate the risk of short-term price fluctuations.
    *   **Monitor the RSI** and consider trimming the position if it remains in overbought territory for an extended period.
    *   **Review the duplicate earnings report** to ensure accuracy.
    *   Given the high existing profit margins and ROE, future growth may be harder to come by.
    *   **Diversification** is highly recommended given the high MDD

This report provides a comprehensive overview based on the data provided. Further due diligence, including a review of the company's financial statements and industry trends, is recommended before making any investment decisions.
